WHO Approves First Malaria Medication Specifically for Babies in Africa

The World Health Organization (WHO) has for the first time approved a malaria medication tailored specifically for babies born in malaria-endemic regions of Africa. This new treatment aims to fill a critical healthcare gap affecting approximately 30 million infants born annually in these areas. Previously, babies were often given dosages designed for older children, which sometimes led to adverse side effects.

To complement this medical advance, the WHO continues to emphasize preventive measures, particularly endorsing the use of insecticide-treated mosquito nets to protect both babies and adults from mosquito bites that transmit malaria.

This development marks a significant step in combating malaria among the most vulnerable population—infants—by providing safer, more appropriate treatment options. The new medication not only addresses previous dosage challenges but also has the potential to reduce malaria-related morbidity and mortality in African children under one year old.

According to the Handelsblatt report, ensuring adequate protection for this large and vulnerable group remains crucial, alongside continued use of established preventive tools like treated mosquito nets. This approval reflects a key health innovation aimed at improving child survival rates in malaria-hit regions.